false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP01. Prevalence, Treatment Patterns and Long-Term ...
FP01. Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker presented data on real-world patients with EGFR-positive lung cancer at the World Lung Conference. The study aimed to estimate the prevalence, treatment patterns, and long-term outcomes of these patients. The prevalence of EGFR-positive patients was found to be 32%, with higher rates in females, never-smokers, and Asians. Disease-free survival was 29 months, with higher rates in stage 1b patients. Overall survival was not reached, but rates were similar for stage 2 and 3a patients. There was no significant difference in survival based on the type of EGFR mutation. The study concluded that patients with EGFR-positive lung cancer had similar outcomes to the placebo control arm of the ADORA trial.
Asset Subtitle
Sabine Schmid
Meta Tag
Speaker
Sabine Schmid
Topic
Early Stage/Localized Disease/Ablative Therapies
Keywords
EGFR-positive lung cancer
prevalence
treatment patterns
long-term outcomes
real-world patients
×
Please select your language
1
English
5
普通话
11
Dutch